首页> International journal of cancer> A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

导出 OA

翻译打印收藏纠错

第一作者： Cathy,Eng

第一单位： The University of Texas M.D. Anderson Cancer Center, Houston, TX.

作者： Cathy,Eng ^[1] ; Alberto,Bessudo ^[2] ; Lowell L,Hart ^[3] ; Aleksey,Severtsev ^[4] ; Oleg,Gladkov ^[5] ; Lothar,Müller ^[6] ; Mikhail V,Kopp ^[7] ; Vladimir,Vladimirov ^[8] ; Robert,Langdon ^[9] ; Bogdan,Kotiv ^[10] ; Sandro,Barni ^[11] ; Ching,Hsu ^[12] ; Ellen,Bolotin ^[13] ; Reinhard,von Roemeling ^[12] ; Brian,Schwartz ^[14] ; Johanna C,Bendell ^[15]

作者单位： The University of Texas M.D. Anderson Cancer Center, Houston, TX. ^[1] cCARE (California Cancer Associates for Research & Excellence), Encinitas, CA. ^[2] Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, FL. ^[3] The Central Clinical Hospital #1, Moscow, Russia. ^[4] Chelyabinsk Regional Clinical Oncological Dispensary, Chelyabinsk, Russia. ^[5] Onkologie Untere Ems Leer-Emden-Papenburg, Leer, Germany. ^[6] Samara Regional Clinical Oncology Dispensary, Samara, Russia. ^[7] Pyatigorsk Oncological Dispensary, Pyatigorsk, Russia. ^[8] Nebraska Methodist Hospital Cancer Center, Omaha, NE. ^[9] Military Medical Academy, Saint Petersburg, Russia. ^[10] Azienda Ospedaliera Treviglio, Treviglio, BG, Italy. ^[11] Daiichi Sankyo, Inc, Edison, NJ. ^[12] Bayer HealthCare, Whippany, NJ, (Employed at Daiichi Sankyo, Inc. At Time of Manuscript Preparation). ^[13] ArQule, Inc, Burlington, MA. ^[14] Tennessee Oncology/Sarah Cannon Research Institute, Nashville, TN. ^[15]

关键词 KRAS wild-type MET inhibitor irinotecan metastatic colorectal cancer tivantinib